Clinical trial
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate…
NCT00005627 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00005627 |
|---|---|
| Title | Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | A Phase I Study of Estramustine, Taxotere and Carboplatin (ETP) in Patients With Horomone Refractory Prostate Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, docetaxel, estramustine phosphate sodium |
| Start date | Mar 1, 1999 |
| Completion | Apr 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: